2018
Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry
Tamborlane WV, Chang P, Kollman C, Klingensmith GJ, Ruedy K, Gal RL, Van Name M, Bacha F, Willi S, Beck RW, Consortium F. Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2018, 19: 1379-1384. PMID: 30175440, DOI: 10.1111/pedi.12763.Peer-Reviewed Original ResearchConceptsType 2 diabetesT2D durationT2D patientsClinical trialsEligibility criteriaPlacebo-assigned subjectsPercentage of patientsCurrent clinical trialsRestrictive eligibility criteriaBaseline HbA1cHbA1c levelsClinical characteristicsClinic registryRegistry enrollmentInvestigational treatmentPatientsCurrent trialTrialsNew drugsMonthsHbA1cRatio of femaleDiabetesRegistryEnrollment
2015
Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes
Mazaika PK, Weinzimer SA, Mauras N, Buckingham B, White NH, Tsalikian E, Hershey T, Cato A, Aye T, Fox L, Wilson DM, Tansey MJ, Tamborlane W, Peng D, Raman M, Marzelli M, Reiss AL. Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes. Diabetes 2015, 65: 476-485. PMID: 26512024, PMCID: PMC4747456, DOI: 10.2337/db15-1242.Peer-Reviewed Original ResearchConceptsEarly-onset type 1 diabetesType 1 diabetesBlood glucose levelsWhite matter volumeGlucose levelsMatter volumeTime pointsBrain volumeAge-matched control subjectsCortical gray matter volumeMeasures of hyperglycemiaMean HbA1c levelCurrent treatment guidelinesManagement of diabetesRapid brain maturationGray matter volumeTime of scanCortical surface areaHbA1c levelsTreatment guidelinesControl subjectsGlycemic variationsLongitudinal time pointsBrain maturationDiabetes
2005
Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study
Tamborlane WV, Kollman C, Steffes MW, Ruedy KJ, Dongyuan X, Beck RW, Chase P, Fox LA, Wilson DM, Tsalikian E. Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study. Pediatric Diabetes 2005, 6: 13-16. PMID: 15787896, DOI: 10.1111/j.1399-543x.2005.00088.x.Peer-Reviewed Original ResearchConceptsDCA 2000Central laboratory valuesHbA1c valuesClinical centersLaboratory valuesComplications Trial/EpidemiologyType 1 diabetes mellitusMean differenceDiabetes researchBaseline HbA1c levelsHemoglobin A1c levelsCentral laboratoryOutpatient clinical trialAdditional blood samplesCentral laboratory methodHbA1c levelsA1c levelsDiabetes mellitusDiabetes practiceDiabetes controlDiabetes InterventionsClinical trialsSame visitBlood samplesReference standard
2002
Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups
Ahern JA, Boland EA, Doane R, Ahern JJ, Rose P, Vincent M, Tamborlane WV. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatric Diabetes 2002, 3: 10-15. PMID: 15016169, DOI: 10.1034/j.1399-5448.2002.30103.x.Peer-Reviewed Original ResearchDiabetes programContinuous subcutaneous insulin infusion (CSII) therapySubcutaneous insulin infusion therapyDiabetes-related adverse eventsDaily insulin dosesMean HbA1c levelPrimary efficacy outcomeSevere hypoglycemic eventsPatients 18 monthsPrimary safety measureInsulin infusion therapyYr of ageEfficacy outcomesHbA1c levelsAdverse eventsInjection therapyYounger patientsPump treatmentDiabetes controlHypoglycemic eventsInsulin dosesInfusion therapyTherapeutic alternativeClinic settingClinical data